News

India’s Translumina Presents 10-year safety data of Drug Eluting Stents

First Company in the world to present long term safety results

Indian medical device company Translumina Therapeutics LLP achieves a special feat of becoming the first company in the world to demonstrate a 10-year patient safety and efficacy data of its drug eluting stent (DES) Yukon Choice PC. This is for the first time that a decade long research data has been presented for the efficacy and safety of DES since its launch in 2001, as no other research has published data of more than 5 years.

The research findings of a randomized control trial called ISAR-TEST 4 were presented by leading cardiac expert from Germany, Dr. Sebastian Kufner at the prestigious 2018 American Heart Association Scientific Sessions at Chicago, Illinois, United States, today in the presence of leading cardiologists from all over the world.

“It was a privilege for me to present the first long-term data of Yukon Choice PC DES of 10 years efficacy and safety. This will not only prove the efficacy and safety of DES for long term, but also gives boost for the long-term success of the procedure of angioplasty after the launch of DES”, said Dr Kufner, Associate Professor of Cardiology, German Heart Centre, Munich, Germany.

Mr. Gurmit Singh Chugh, Managing Director, Translumina Therapeutics, who was present during the data presentation, was very excited with results and its presentation at this prestigious forum. He stated “We are excited with this first long term data which is a new milestone and a benchmark for efficacy and safety of DES Worldwide. Yukon Choice PC showing the lowest Stent thrombosis rates compared to Xience and Cypher at 10 years creates a strong testimony that this technology is truly next generation in terms of safety.

Prof Adnan Kastrati, Principal Investigator of ISAR Test 4 and the Director of Cardiac Cath Lab at German Heart Centre, Munich stated “The 10-year results achieved in this trial with new-generation DES provide a strong argument against still existing concerns about the long-term safety of DES”.

“The long-term data from the ISAR-TEST 4 trial  shall not only increase the confidence of Cardiologists on these new generation DES but shall also reassure patients who have received these DES for the treatment of coronary artery disease. I am pleased that one of these technologies is coming from India which shall create immense positivity and high acceptance for Indian manufactured DES world over” said Dr. Robert Byrne, Deputy Director of Cardiology at German Heart Center and Senior Author of the presented study.

 

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.
Show More

Related Articles

Leave a Reply

Close